Lars Jorgensen - Novo Nordisk CEO Pres
| NONOF Stock | USD 105.50 0.58 0.55% |
Insider
Lars Jorgensen is CEO Pres of Novo Nordisk AS
| Age | 57 |
| Phone | 45 44 44 88 88 |
| Web | https://www.novonordisk.com |
Novo Nordisk Management Efficiency
The company has return on total asset (ROA) of 0.2169 % which means that it generated a profit of $0.2169 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.72 %, meaning that it generated $0.72 on every $100 dollars invested by stockholders. Novo Nordisk's management efficiency ratios could be used to measure how well Novo Nordisk manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 5 records | INSIDER Age | ||
| David Innes | Northwest Biotherapeutics | N/A | |
| Stephen JD | Geron | 74 | |
| Linda JD | Northwest Biotherapeutics | 67 | |
| Jean Davis | Northwest Biotherapeutics | 51 | |
| , MBA | Northwest Biotherapeutics | 64 | |
Management Performance
| Return On Equity | 0.72 | |||
| Return On Asset | 0.22 |
Novo Nordisk AS Leadership Team
Elected by the shareholders, the Novo Nordisk's board of directors comprises two types of representatives: Novo Nordisk inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novo. The board's role is to monitor Novo Nordisk's management team and ensure that shareholders' interests are well served. Novo Nordisk's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novo Nordisk's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Monique Carter, Head VP | ||
| Maziar Doustdar, Executive Vice President International Operations | ||
| Lars Jorgensen, CEO Pres | ||
| Marcus Schindler, Head EVP | ||
| Karsten Knudsen, CFO, Executive Vice President | ||
| Henrik Wulff, Executive Vice President Product Supply | ||
| Ludovic Helfgott, Executive Vice President of Biopharm | ||
| Camilla Sylvest, Executive Vice President Commercial Strategy & Corporate Affairs | ||
| Douglas Langa, Head VP | ||
| Martin Lange, Head VP |
Novo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Novo Nordisk a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.72 | |||
| Return On Asset | 0.22 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.43 % | |||
| Current Valuation | 292.82 B | |||
| Shares Outstanding | 1.72 B | |||
| Shares Owned By Institutions | 38.87 % | |||
| Price To Earning | 41.24 X | |||
| Price To Book | 26.64 X | |||
| Price To Sales | 1.73 X |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Novo Pink Sheet
When determining whether Novo Nordisk AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novo Nordisk's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novo Nordisk As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novo Nordisk As Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.